- Home
- COLL vs AAMI Comparison
COLL vs AAMI Comparison
Compare COLL & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- AAMI
- Stock Information
- Founded
- COLL 2002
- AAMI 1980
- Country
- COLL United States
- AAMI United States
- Employees
- COLL N/A
- AAMI N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- AAMI Investment Managers
- Sector
- COLL Health Care
- AAMI Finance
- Exchange
- COLL Nasdaq
- AAMI Nasdaq
- Market Cap
- COLL 1.0B
- AAMI 978.8M
- IPO Year
- COLL 2015
- AAMI N/A
- Fundamental
- Price
- COLL $29.13
- AAMI $25.75
- Analyst Decision
- COLL Strong Buy
- AAMI Hold
- Analyst Count
- COLL 5
- AAMI 1
- Target Price
- COLL $43.60
- AAMI $27.00
- AVG Volume (30 Days)
- COLL 294.2K
- AAMI 155.4K
- Earning Date
- COLL 02-27-2025
- AAMI 02-06-2025
- Dividend Yield
- COLL N/A
- AAMI 0.16%
- EPS Growth
- COLL 757.11
- AAMI 43.23
- EPS
- COLL 2.16
- AAMI 2.22
- Revenue
- COLL $599,245,000.00
- AAMI $505,600,000.00
- Revenue This Year
- COLL $13.25
- AAMI $5.10
- Revenue Next Year
- COLL $17.67
- AAMI $7.83
- P/E Ratio
- COLL $13.47
- AAMI $11.56
- Revenue Growth
- COLL 9.62
- AAMI 18.52
- 52 Week Low
- COLL $28.39
- AAMI $21.45
- 52 Week High
- COLL $42.29
- AAMI $31.52
- Technical
- Relative Strength Index (RSI)
- COLL 37.61
- AAMI N/A
- Support Level
- COLL $29.39
- AAMI N/A
- Resistance Level
- COLL $30.39
- AAMI N/A
- Average True Range (ATR)
- COLL 1.00
- AAMI 0.00
- MACD
- COLL -0.24
- AAMI 0.00
- Stochastic Oscillator
- COLL 11.04
- AAMI 0.00
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a diversified, multi-boutique asset management company. It offers institutional investors across the globe access to a wide array of systematic strategies designed to meet a range of risk and return objectives.